Mild Cardiotoxicity and Continued Trastuzumab Treatment in the Context of HER2-Positive Breast Cancer

Breast cancer is the leading cause of cancer death in women worldwide. Trastuzumab, the main HER2-targeted treatment, faces limitations due to potential cardiotoxicity. The management of patients with mild cardiotoxicity on trastuzumab remains uncertain, resulting in treatment discontinuation and ne...

Descripción completa

Detalles Bibliográficos
Autores principales: de la Brassinne Bonardeaux, Orianne, Born, Benjamin, Moonen, Marie, Lancellotti, Patrizio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10650899/
https://www.ncbi.nlm.nih.gov/pubmed/37959174
http://dx.doi.org/10.3390/jcm12216708

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10650899/
https://www.ncbi.nlm.nih.gov/pubmed/37959174
http://dx.doi.org/10.3390/jcm12216708

Ejemplares similares